 |
[Alpha Biz=(Chicago) Reporter Paul Lee] Samsung Pharmaceutical is expected to carry out a large-scale paid-in capital increase for shareholders to raise costs for phase III clinical trials of new drug candidates for Alzheimer's disease.
Samsung Pharmaceutical Co. held a board meeting on the 17th and issued 27 million new shares worth 50 billion won to decide on a paid-in capital increase in the form of a general public offering of disqualified shares after allocating shareholders. The estimated value of new shares is 1,777 won, and the final fixed date is January 24 next year.
The new share allocation date is December 20, and the number of new shares per share is 0.4022628267 shares. The listing date of the issued new shares is February 21 next year. The subscription date for the new shares of the old shareholders (existing shareholders) is January 29-30 next year. The general public subscription for the remaining disqualified shares after the subscription for new shares of the old shares is scheduled to take place on Feb. 1-2 next year.
Alphabiz Reporter Paul Lee(hoondork1977@alphabiz.co.kr)
